{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:01:09Z","timestamp":1782831669605,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To predict prostate cancer using novel biomarker ratios and create a predictive scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data of a total of 703 patients who consulted Urology Department of Selayang Hospital between January 2013 and December 2017 and underwent prostate biopsy were screened retrospectively. Prostate specific antigen (PSA) levels, prostate volumes (PV), neutrophil and lymphocyte counts, neutrophil-to-lymphocyte ratio (NLR), Prostate specific antigen density (PSAD) and histopathology were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ages ranged from 43 to 89\u00a0years, divided into 2 groups as per biopsy results; positive for prostate cancer (n\u2009=\u2009290, 41.3%) and negative for malignancy (n\u2009=\u2009413; 58.7%). Intergroup comparative evaluations were performed. Independent variables with\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 in the univariate analysis were age, DRE, PV, NLR, PSAD. A scoring system was modelled using NLR\u2009&lt;\u20090.9, PSAD\u2009&gt;\u20090.4, Age\u2009&gt;\u200970 and DRE. A score of 2 or more predicted prostate cancer with a Sensitivity of 83.8% and Specificity of 86.4%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NLR is shown to be good predictor for prostate cancer its usage in this scoring system affords more disease specificity as compared to PSA alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-022-00956-2","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T03:03:39Z","timestamp":1643771019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting the diagnosis of prostate cancer with a scoring system based on novel biomarkers"],"prefix":"10.1186","volume":"22","author":[{"given":"Durvesh Lachman","family":"Jethwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lameena Lalitha","family":"Sivamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charng Chee","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"956_CR1","unstructured":"Malaysia National Cancer Registry Report 2007\u20132011. http:\/\/www.care.upm.edu.my\/dokumen\/13603_NCR2007.pdf. Accessed 07 Sept 2020"},{"key":"956_CR2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00345-015-1494-7","volume":"33","author":"T Langsenlehner","year":"2015","unstructured":"Langsenlehner T, Thurner EM, Krenn-Pilko S, et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol. 2015;33:1661\u20137. https:\/\/doi.org\/10.1007\/s00345-015-1494-7.","journal-title":"World J Urol"},{"key":"956_CR3","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1111\/bju.12531","volume":"114","author":"P Nuhn","year":"2014","unstructured":"Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, Antonarakis ES. NLR predicts OS in men with mCRPC receiving docetaxel. BJU Int. 2014;114:E11\u20137. https:\/\/doi.org\/10.1111\/bju.12531.","journal-title":"BJU Int"},{"issue":"6","key":"956_CR4","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"956_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"956_CR6","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/ijc.27441","volume":"130","author":"D Buergy","year":"2012","unstructured":"Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130(12):2747\u201360. https:\/\/doi.org\/10.1002\/ijc.27441.","journal-title":"Int J Cancer"},{"issue":"6","key":"956_CR7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362\u20137. https:\/\/doi.org\/10.1016\/j.urology.2014.02.035.","journal-title":"Urology"},{"issue":"2","key":"956_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74(2):197\u2013203. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.003.","journal-title":"Eur Urol"},{"issue":"12","key":"956_CR9","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/ijc.28313","volume":"133","author":"AT Toriola","year":"2013","unstructured":"Toriola AT, Laukkanen JA, Kurl S, Nyyss\u00f6nen K, Ronkainen K, Kauhanen J. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer. 2013;133(12):2961\u20137. https:\/\/doi.org\/10.1002\/ijc.28313.","journal-title":"Int J Cancer"},{"issue":"6","key":"956_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4103\/1008-682X.164198","volume":"18","author":"JJ Oh","year":"2016","unstructured":"Oh JJ, Kwon O, Lee JK, Byun SS, Lee SE, Lee S, Hong SK. Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. Asian J Androl. 2016;18(6):937\u201341. https:\/\/doi.org\/10.4103\/1008-682X.164198.","journal-title":"Asian J Androl"},{"issue":"31","key":"956_CR11","doi-asserted-by":"publisher","first-page":"32169","DOI":"10.18632\/oncotarget.5081","volume":"6","author":"T Kawahara","year":"2015","unstructured":"Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N, Izumi K, Yokomizo Y, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Yao M, Miyamoto H, Uemura H. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget. 2015;6(31):32169\u201376. https:\/\/doi.org\/10.18632\/oncotarget.5081.","journal-title":"Oncotarget"},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12885-017-3614-9","volume":"17","author":"H Wang","year":"2017","unstructured":"Wang H, Gu L, Wu Y, et al. The values of neutrophil-lymphocyte ratio and\/or prostate-specific antigen in discriminating real Gleason score \u2265 7 prostate cancer from group of biopsy-based Gleason score \u2264 6. BMC Cancer. 2017;17:629. https:\/\/doi.org\/10.1186\/s12885-017-3614-9.","journal-title":"BMC Cancer"},{"issue":"11\u201312","key":"956_CR13","doi-asserted-by":"publisher","first-page":"E383","DOI":"10.5489\/cuaj.3550","volume":"10","author":"MI Gokce","year":"2016","unstructured":"Gokce MI, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J. 2016;10(11\u201312):E383\u20137. https:\/\/doi.org\/10.5489\/cuaj.3550.","journal-title":"Can Urol Assoc J"},{"key":"956_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12894-019-0553-6","volume":"19","author":"S Carbunaru","year":"2019","unstructured":"Carbunaru S, Nettey OS, Gogana P, et al. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. BMC Urol. 2019;19:121. https:\/\/doi.org\/10.1186\/s12894-019-0553-6.","journal-title":"BMC Urol"},{"issue":"8","key":"956_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104917","volume":"9","author":"J Lim","year":"2014","unstructured":"Lim J, Bhoo-Pathy N, Sothilingam S, Malek R, Sundram M, et al. Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. PLoS ONE. 2014;9(8): e104917. https:\/\/doi.org\/10.1371\/journal.pone.0104917.","journal-title":"PLoS ONE"},{"issue":"4","key":"956_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvi\u00e8re O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003.","journal-title":"Eur Urol"},{"issue":"10071","key":"956_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, PROMIS Study Group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1.","journal-title":"Lancet"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-00956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-00956-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-00956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T03:04:01Z","timestamp":1643771041000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-00956-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-00956-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-858055\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and ethics approval was granted by the Medical Research Ethics Committee (MREC) of the Ministry of Health of Malaysia. The study is registered with the National Medical Research Register (NMRR) of the Ministry of Health of Malaysia with the following registration number: NMRR-18-363-39615. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have\u00a0given consent to publication\u00a0of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}